Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome

Sponsor
European School of Advanced Studies in Ophthalmology
Study ID
NCT05080803
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Retrospective multi-center observational study on functional and morphological outcome of initial therapy for DME according to ESASO Morphologic Classification.

Key Dates

Start date
Jun 1, 2021
Status verified
Sep 2023
Primary completion
Dec 23, 2021
Completion
Jul 26, 2022

Study Design

Enrollment
608 participants (actual)

Arms

  • Arm: Early DME
    Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
  • Arm: Advanced DME
    Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
  • Arm: Severe DME
    Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately
  • Arm: Atrophic diabetic maculopathy
    Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately

Primary Outcome Measure

Functional and morphological improvement in DME after initial therapeutic loading phase, according to ESASO stage of progression of the disease. [ Time Frame: Four months ]

Related Studies